Study of immunotherapy side effects in melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how people with advanced melanoma (a serious skin cancer) feel during treatment with immunotherapy. It aims to better understand the symptoms they experience, so doctors can help manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You can speak and read English
- You have been diagnosed with stage IIB, III, or IV melanoma (a type of skin cancer)
- You are scheduled to start treatment with an immune checkpoint inhibitor (a type of immunotherapy) at UCSF
- You are willing to sign a consent form to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks people with melanoma (and certain related skin conditions) to complete questionnaires about quality of life, lifestyle, and mental well-being. Your answers can help researchers understand what affects day-to-day life and support for people with melanoma.
This study looks at whether a type of cancer treatment called immune checkpoint inhibitors can cause side effects in your joints or muscles. You will have an ultrasound and a physical exam to check for these problems.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at long-term side effects in people who received immunotherapy for advanced melanoma and have had their cancer controlled for at least 3 years. Researchers want to understand how these treatments affect patients years later.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.